Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386036332> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4386036332 endingPage "55" @default.
- W4386036332 startingPage "55" @default.
- W4386036332 abstract "Background Prohibitin is a widely expressed intracellular protein that is distributed in various compartments, where they exert different biological functions accordingly. Prohibitins have displayed both protumorigenic and antitumorigenic roles in cancer formation. Depending on the type of cancer and the localization of prohibitin, studies have shown that it exerts a different biological role. Aim This study aims to investigate prohibitin level in Egyptian patients with chronic myeloid leukemia (CML) and to evaluate its correlation with disease activity and response to first-line tyrosysine kinase inhibitor treatment. Patients and methods Prohibitin level was measured using enzyme-linked immunosorbent assay in 80 CML patients in the chronic phase. They were recruited from the clinical hematology division of Internal Medicine Department, Ain Shams University Hospitals. They were matched to 10 healthy volunteers as a control group. Results In our study, we have demonstrated that prohibitin levels were significantly higher in patients with CML than in the control participants (P=0.002). Prohibitin levels were significantly higher in CML patients with an active disease status (P=0.001). In addition, significantly higher levels of prohibitin in CML patients were associated with poor response to first generation TKIs (P=0.001). Receiver-operating characteristic curve was applied. A serum level of prohibitin higher than 289 is a good predictor for poor response to first generation TKIs as per response assessment by PCR for BCR-ABL (area under the curve=0.67, sensitivity and specificity 58.33 and 80.56, respectively). Conclusion Prohibitin is overexpressed in CML patients and has a possible impact on disease activity and response to treatment in CML patients that warrants further investigations." @default.
- W4386036332 created "2023-08-22" @default.
- W4386036332 creator A5014960197 @default.
- W4386036332 creator A5015113195 @default.
- W4386036332 creator A5045125714 @default.
- W4386036332 creator A5077791348 @default.
- W4386036332 creator A5080539800 @default.
- W4386036332 creator A5092669924 @default.
- W4386036332 date "2023-01-01" @default.
- W4386036332 modified "2023-09-25" @default.
- W4386036332 title "Clinical significance of serum prohibitin in chronic myeloid leukemia patients on first-line tyrosine kinase inhibitors" @default.
- W4386036332 doi "https://doi.org/10.4103/ejh.ejh_57_21" @default.
- W4386036332 hasPublicationYear "2023" @default.
- W4386036332 type Work @default.
- W4386036332 citedByCount "0" @default.
- W4386036332 crossrefType "journal-article" @default.
- W4386036332 hasAuthorship W4386036332A5014960197 @default.
- W4386036332 hasAuthorship W4386036332A5015113195 @default.
- W4386036332 hasAuthorship W4386036332A5045125714 @default.
- W4386036332 hasAuthorship W4386036332A5077791348 @default.
- W4386036332 hasAuthorship W4386036332A5080539800 @default.
- W4386036332 hasAuthorship W4386036332A5092669924 @default.
- W4386036332 hasConcept C121608353 @default.
- W4386036332 hasConcept C126322002 @default.
- W4386036332 hasConcept C143998085 @default.
- W4386036332 hasConcept C203014093 @default.
- W4386036332 hasConcept C2775894526 @default.
- W4386036332 hasConcept C2777938653 @default.
- W4386036332 hasConcept C2778461978 @default.
- W4386036332 hasConcept C2778729363 @default.
- W4386036332 hasConcept C2778820342 @default.
- W4386036332 hasConcept C2779134260 @default.
- W4386036332 hasConcept C2781197716 @default.
- W4386036332 hasConcept C28859421 @default.
- W4386036332 hasConcept C502942594 @default.
- W4386036332 hasConcept C54355233 @default.
- W4386036332 hasConcept C71924100 @default.
- W4386036332 hasConcept C86803240 @default.
- W4386036332 hasConceptScore W4386036332C121608353 @default.
- W4386036332 hasConceptScore W4386036332C126322002 @default.
- W4386036332 hasConceptScore W4386036332C143998085 @default.
- W4386036332 hasConceptScore W4386036332C203014093 @default.
- W4386036332 hasConceptScore W4386036332C2775894526 @default.
- W4386036332 hasConceptScore W4386036332C2777938653 @default.
- W4386036332 hasConceptScore W4386036332C2778461978 @default.
- W4386036332 hasConceptScore W4386036332C2778729363 @default.
- W4386036332 hasConceptScore W4386036332C2778820342 @default.
- W4386036332 hasConceptScore W4386036332C2779134260 @default.
- W4386036332 hasConceptScore W4386036332C2781197716 @default.
- W4386036332 hasConceptScore W4386036332C28859421 @default.
- W4386036332 hasConceptScore W4386036332C502942594 @default.
- W4386036332 hasConceptScore W4386036332C54355233 @default.
- W4386036332 hasConceptScore W4386036332C71924100 @default.
- W4386036332 hasConceptScore W4386036332C86803240 @default.
- W4386036332 hasIssue "1" @default.
- W4386036332 hasLocation W43860363321 @default.
- W4386036332 hasOpenAccess W4386036332 @default.
- W4386036332 hasPrimaryLocation W43860363321 @default.
- W4386036332 hasRelatedWork W1538058163 @default.
- W4386036332 hasRelatedWork W1974032072 @default.
- W4386036332 hasRelatedWork W2181510334 @default.
- W4386036332 hasRelatedWork W2278966712 @default.
- W4386036332 hasRelatedWork W2781987667 @default.
- W4386036332 hasRelatedWork W2909695583 @default.
- W4386036332 hasRelatedWork W3151222619 @default.
- W4386036332 hasRelatedWork W3158921720 @default.
- W4386036332 hasRelatedWork W3207807551 @default.
- W4386036332 hasRelatedWork W77027797 @default.
- W4386036332 hasVolume "48" @default.
- W4386036332 isParatext "false" @default.
- W4386036332 isRetracted "false" @default.
- W4386036332 workType "article" @default.